Amaris Murray
Family · Baltimore, MDNPI 1841844222
Payments from drug & device makers
Across 246 payments — averaging $27.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Biohaven Pharmaceuticals, Inc.$864
- Otsuka America Pharmaceutical, Inc.$713
- AstraZeneca$673
- Neurocrine Biosciences, Inc.$511
- Lundbeck LLC$406
- plus $3K from 23 others
What the payments were for
- Consulting fees$80012%
- Food & beverage$5,87188%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 66 | $1,002 |
| Biohaven Pharmaceuticals, Inc. | 3 | $864 |
| Otsuka America Pharmaceutical, Inc. | 23 | $713 |
| AstraZeneca | 22 | $673 |
| Neurocrine Biosciences, Inc. | 23 | $511 |
| Lundbeck LLC | 17 | $406 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 17 | $370 |
| Viiv Healthcare Company | 9 | $305 |
| Alkermes, Inc. | 11 | $244 |
| Axsome Therapeutics, Inc. | 7 | $233 |
| Johnson & Johnson | 1 | $191 |
| Indivior Inc. | 7 | $186 |
| Vanda Pharmaceuticals Inc. | 7 | $161 |
| GSK | 7 | $157 |
| Dexcom, Inc. | 1 | $118 |
| E.r. Squibb & Sons, L.L.C. | 4 | $102 |
| Orexo US, Inc. | 3 | $65 |
| Phadia US Inc. | 2 | $49 |
| Astellas Pharma US Inc | 3 | $48 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $39 |
| Pfizer | 2 | $38 |
| Lilly USA, LLC | 2 | $34 |
| Corium, LLC | 1 | $29 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $29 |
| Exact Sciences | 1 | $26 |
| Collegium Pharmaceutical, Inc. | 1 | $25 |
| Gilead | 1 | $23 |
| Novo Nordisk | 1 | $18 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$800
- INVEGA SUSTENNA$191
- INVEGA TRINZA$191
- ABILIFY ASIMTUFII$125
- ABILIFY MAINTENA$125
- REXULTI$125
- DOVATO$122
- AIRSUPRA$122
- Auvelity$121
- DEXCOM G7 GSS (161)$118
How this compares
$6,671 in reported general payments places this provider in the 95th percentile of 2,843 family providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 62 | $110,257 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 18 | $71,867 |
| RybelsusSemaglutide | 13 | $34,926 |
| Nurtec OdtRimegepant Sulfate | 13 | $25,274 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 37 | $24,706 |
| CaplytaLumateperone Tosylate | 11 | $19,640 |
| RexultiBrexpiprazole | 13 | $18,420 |
| TrulicityDulaglutide | 11 | $10,502 |
| FarxigaDapagliflozin Propanediol | 13 | $8,735 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 16 | $7,812 |
| Varenicline Tartrate | 29 | $7,239 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 18 | $7,092 |
| BrilintaTicagrelor | 11 | $5,277 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 78 | $2,355 |
| Gabapentin | 96 | $1,395 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $1,002 | $110,25762 claims |
| GileadBiktarvy | $23 | $71,86718 claims |
| Novo NordiskRybelsus | $18 | $34,92613 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $157 | $31,79855 claims |
| PfizerNurtec Odt | $38 | $25,27413 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $370 | $19,64011 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $713 | $18,42013 claims |
| AstraZenecaFarxiga, Brilinta | $673 | $14,01224 claims |
| Lilly USA, LLCTrulicity | $34 | $10,50211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,843 family providers in Maryland.
Other family in Baltimore
- Hazel Jones-ParkerBaltimore$96K
- Brittany WilsonBaltimore$88K
- Lisa ScottiBaltimore$35K
- Leah HartBaltimore$32K
- Jinae ArneklevBaltimore$24K
- Valerie OwenBaltimore$12K
- Eldho ChackoBaltimore$12K
- Melonie OwusuBaltimore$10K
- Amanda NevinBaltimore$9K
- Suryamol ChackoBaltimore$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.